Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 9/20 | 0.56 |
| ▸ | KIT | P10721 | 6/20 | 0.56 |
| ▸ | AXL | P30530 | 2/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 5/20 | 0.40 |
| ▸ | WNT3A | P56704 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.37 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13007023 | 1.00 | FLT3 (0.56) | FLT3KITAXLBACE1LMNA | |
| SCHEMBL13006580 | 0.94 | FLT3 (0.47) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL14275718 | 0.91 | AXL (0.46) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL14275722 | 0.91 | FLT3 (0.46) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL13006581 | 0.91 | FLT3 (0.46) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL13006582 | 0.90 | FLT3 (0.45) | FLT3KITAXLBACE1LMNA | |
| SCHEMBL13006845 | 0.90 | FLT3 (0.45) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL14275709 | 0.90 | AXL (0.52) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL14275725 | 0.90 | FLT3 (0.45) | FLT3KITAXLBACE1JAK2 | |
| SCHEMBL14275726 | 0.90 | FLT3 (0.45) | FLT3KITAXLBACE1WNT3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1791830-B1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMA (US) | 2010-12-29 | — | — | EP | disclosed |
| US-7329652-B2 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARAMACEUTICALS INCORPORATED (US) | 2008-02-12 | — | — | US | disclosed |
| EP-1791830-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2007-06-06 | — | — | EP | disclosed |
| WO-2006034116-A1 | DIAMINOTRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063756-A1 | Diaminotriazole compounds useful as protein kinase inhibitors | JAK2, JAK3, JAK1 | FLT3 43/4885KIT 851/4885AXL 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.